《CSCO非小细胞肺癌诊疗指南2024》更新解读  

Updated interpretation of Chinese Society of Clinical Oncology(CSCO)Guidelines forthe Diagnosis and Treatment of Non-small Cell Lung Cancer 2024

作　　者：徐瑜 李梦侠 XU Yu;LI Mengxia(Department of Oncology,Army Medical Center of PLA,Chongqing 400042,China)

机构地区：[1]陆军特色医学中心肿瘤科,重庆400042

出　　处：《现代医药卫生》2024年第11期1801-1808,共8页Journal of Modern Medicine & Health

摘　　要：2024年4月,中国临床肿瘤学会(CSCO)正式发布《CSCO非小细胞肺癌诊疗指南2024》(以下简称《2024版CSCO非小细胞肺癌(NSCLC)指南》)。该指南在2023年版的基础上,继续秉承循证医学证据、立足诊疗药物可及性,兼顾地区发展差异和药物经济学成本,汇总专家意见,对非小细胞肺癌的诊疗进展进行及时更新。该文旨在对《2024版CSCO NSCLC指南》更新部分进行梳理和剖析,重点解析免疫治疗及靶向治疗的更新要点及其相应的循证医学证据。The Chinese Society of Clinical Oncology(CSCO)Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer 2024 Hereinafter referred to as the CSCO Guidelines for Non Small Cell Lung Cancer(NSCLC)in 2024 was officially released in April 2024.The new version of the CSCO Guidelines for NSCLC in 2024 adhered to the evidence-based medical evidence,focused on the accessibility of drugs,taking into account regional development differences and pharmacoeconomic costs,summarizing expert opinions,and timely updating the diagnosis and treatment of NSCLC on the basis of the 2023 version.This paper aimed to sort out and analyze the updated part of the CSCO Guidelines for NSCLC in 2024,focusing on the update points of immunotherapy and targeted therapy and the corresponding evidence-based medical evidence.

关 键 词：非小细胞肺癌 诊疗进展 免疫治疗 靶向治疗 循证医学 指南解读 

分 类 号：R734.2[医药卫生—肿瘤]